Bio-Solutions Corp. Receives First LOI in Burkina Faso for GreenEx(TM), Malaria Combating Organic Insecticide

Published: Mar 22, 2010

MONTREAL, QUEBEC, CANADA--(Marketwire - March 19, 2010) - Bio-Solutions Corp. (OTCBB: BISU), is proud to announce that CEO and President. Dr. Gilles Chaumillon has completed his visit to Burkina Faso, with the accompaniment of Mr. Hama Arba Diallo, member of Bio-Solutions Corp. advisory committee and deputy of the National Assembly of Burkina Faso since 2007, and is currently the Fifth Vice-President of the National Assembly.

Upon departure from Burkina Faso en route to the Democratic Republic of Congo (DRC), Dr. Chaumillon expressed great excitement and promise after meeting with the Mayor of Dori, a city in Burkina Faso. "We have a signed Letter of Interest (LOI) regarding the implementation and water treatment with GREENEX™ in hand. GREENEX™ is our organic insecticide available in solid or liquid form which neutralizes and eradicates up to 98% of the mosquito larvae, within a 24 hours period. Municipal funding application will be submitted before the end of April." stated Dr. Chaumillon. "One of my representatives in Africa will follow up and guide the application for funding process. Several ministries have showed a great interest, for Pilot studies to commence in their given districts. This First LOI represents a milestone and a great opportunity for Bio-Solutions Corp, at an exponential level." In addition to Bio's LOI, Dr. Chaumillon was delighted to meet with government and health officials from Mali before his return to North America.

According to Malaria Foundation International, every 30 seconds, a child somewhere dies of malaria. Previously extremely widespread, the malaria is now mainly confined to Africa, Asia and Latin America. The problems of controlling malaria in these countries are aggravated by inadequate health structures and poor socioeconomic conditions. The situation has become even more complex over the last few years with the increase in resistance to the drugs normally used to combat the parasite that causes the disease. Over 300 million people are infected, more than one million children (under the age of five years) die by cause of Malaria each year.

For more information on Bio-Solutions Corp. and its products, please visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

Bio-Solutions Corp.
Jakub Hryniewicz

Back to news